{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:53:29Z","timestamp":1794027209638,"version":"4.8.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T20:39:30Z","timestamp":1765226370000},"page":"41-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Juan P.","family":"Horcajada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Milagro","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2025.11.001_bib1","doi-asserted-by":"crossref","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2025.11.001_bib2","first-page":"24","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","volume":"80","author":"Tamma","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/femsre\/fux043","article-title":"Diversity and regulation of intrinsic \u03b2-lactamases from non-fermenting and other Gram-negative opportunistic pathogens","volume":"41","author":"Juan","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"25","key":"10.1016\/j.idc.2025.11.001_bib7","first-page":"00131","article-title":"Emerging resistance mechanisms to newer beta-lactams in Pseudomonas aeruginosa","volume":"S1198-743X","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"Poirel L ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"Ortiz de la Rosa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib9","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.idc.2025.11.001_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02067-21","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib11","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00039-22","article-title":"Impact of acquired broad-spectrum \u03b2-Lactamases on susceptibility to cefiderocol and newly developed \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"66","author":"Poirel","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00648-22","article-title":"Emergence of KPC-31, a KPC-3 variant associated with ceftazidime-avibactam resistance, in an extensively drug-resistant ST235 Pseudomonas aeruginosa clinical isolate","volume":"66","author":"Faccone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01164-24","article-title":"Mechanisms leading to in vivo ceftazidime\/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections","volume":"68","author":"Herrera","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00981-15","article-title":"Selective sweeps and parallel pathoadaptation drive Pseudomonas aeruginosa evolution in the cystic fibrosis lung","volume":"6","author":"Diaz Caballero","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.idc.2025.11.001_bib16","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2025.11.001_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00089-21","article-title":"Emergence of resistance to novel Cephalosporin-\u03b2-Lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ efflux pump","volume":"65","author":"Gomis-Font","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/jac\/dkad172","article-title":"In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa","volume":"78","author":"Gomis-Font","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","article-title":"Emerging broad-spectrum resistance in Pseudomonas aeruginosa and acinetobacter baumannii: mechanisms and epidemiology","volume":"45","author":"Potron","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jgar.2018.10.020","article-title":"Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates","volume":"16","author":"Costello","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.001_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(03)14959-8","article-title":"Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa","volume":"362","author":"Yokoyama","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2025.11.001_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/AAC.01252-13","article-title":"Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa","volume":"58","author":"Gu\u00e9nard","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01835-17","article-title":"Mutations in gene fusA1 as a novel mechanism of aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa","volume":"62","author":"Bolard","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02583-17","article-title":"Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting","volume":"62","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1128\/AAC.01581-12","article-title":"Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance","volume":"57","author":"Bruchmann","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijantimicag.2016.11.029","article-title":"Resistance to polymyxins in Gram-negative organisms","volume":"49","author":"Jeannot","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007740","article-title":"Pseudomonas aeruginosa population structure revisited","volume":"4","author":"Pirnay","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2025.11.001_bib29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1574-6976.2011.00268.x","article-title":"Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance","volume":"35","author":"Woodford","year":"2011","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.idc.2025.11.001_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"del Barrio-Tofi\u00f1o","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.cmi.2017.06.018","article-title":"Global emergence of the widespread Pseudomonas aeruginosa ST235 clone","volume":"24","author":"Treepong","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cid\/ciu866","article-title":"Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections","volume":"60","author":"Pe\u00f1a","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijantimicag.2018.03.018","article-title":"Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm","volume":"52","author":"Recio","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10096-024-05010-7","article-title":"Genomic epidemiology of Pseudomonas aeruginosa sequence type 111","volume":"44","author":"Matsumara","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib35","first-page":"74","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"5","author":"Bassetti","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.idc.2025.11.001_bib36","first-page":"377","article-title":"Multidrug-resistant bacteria in the community: trends and lessons learned","volume":"30","author":"van Duin","year":"2016","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.idc.2025.11.001_bib37","first-page":"33","article-title":"Diagnostic stewardship to limit antimicrobial resistance","volume":"19","author":"Buehrle","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.idc.2025.11.001_bib38","article-title":"Outcome of infections due to carbapenem-resistant Pseudomonas aeruginosa in hospitalized patients: a multicenter prospective study","volume":"7","author":"Falcone","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib40","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/antibiotics11050626","article-title":"The comparative effectiveness of ceftolozane\/tazobactam versus aminoglycoside- or polymyxin-based regimens in multi-drug-resistant Pseudomonas aeruginosa infections","volume":"11","author":"CaffreyAR","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.11.001_bib41","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40121-022-00687-9","article-title":"Impact of ceftolozane-tazobactam vs. best alternative therapy on clinical outcomes in patients with multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa lower respiratory tract infections","volume":"11","author":"Holger","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idc.2025.11.001_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant pseudomonas aeruginosa: a multicentre cohort study","volume":"28","author":"Almangour","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.001_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.idc.2025.11.001_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02340-18","article-title":"A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib45","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jiph.2022.08.020","article-title":"Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study","volume":"15","author":"Hakeam","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.idc.2025.11.001_bib47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infec"},{"key":"10.1016\/j.idc.2025.11.001_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1533952","article-title":"The efficacyand safety of ceftazidime\/avibactam or polymyxin B based regimens for carbapenem-resistant Pseudomonas aeruginosa infection: a multicenter real-world and propensity score-matched study","volume":"16","author":"Long","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.idc.2025.11.001_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"24","key":"10.1016\/j.idc.2025.11.001_bib50","first-page":"00648","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"S1473-3099","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib51","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","author":"Shah","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12866-019-1522-7","article-title":"In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa","volume":"19","author":"Young","year":"2019","journal-title":"BMC Microbiol"},{"issue":"7","key":"10.1016\/j.idc.2025.11.001_bib55","first-page":"e02002","article-title":"In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated worldwide in 2015","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib56","first-page":"677","article-title":"Antimicrobial activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates collected worldwide in 2017","volume":"76","author":"Sader","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib57","first-page":"738","article-title":"RESTORE-IMI 1: a randomized trial comparing imipenem\u2013relebactam with colistin plus imipenem in imipenem-non-susceptible infections","volume":"20","author":"Motsch","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib58","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib59","first-page":"S544","article-title":"Clinical and microbiological characteristics of cefiderocol: a novel siderophore cephalosporin","volume":"71","author":"Sato","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.001_bib60","article-title":"In vitro activity of cefiderocol against clinical isolates of gram-negative Bacilli collected worldwide","volume":"66","author":"Kazmierczak","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib61","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol,in Gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib62","first-page":"e846","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in critically ill patients","volume":"75","author":"Falcone","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib63","series-title":"Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study","author":"Ramirez","year":"2024"},{"key":"10.1016\/j.idc.2025.11.001_bib64","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib65","series-title":"Investigator driven randomized controlled trial of cefiderocol versus standard therapy for healthcare associated and hospital acquired Gram-negative bloodstream infection (GAME CHANGER trial)","author":"Paterson","year":"2024"},{"key":"10.1016\/j.idc.2025.11.001_bib66","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo \u03b2 lactamase producing gram negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.11.001_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam avibactam against enterobacteriaceae and Pseudomonas aeruginosa clinical isolates worldwide (2012\u20132015)","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.idc.2025.11.001_bib69","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/cid\/ciw684","article-title":"The effectiveness and safety of high-dose colistin: prospective cohort study","volume":"63","author":"Benattar","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib70","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.01015-06","article-title":"Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients","volume":"51","author":"Hachem","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib71","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc2358","article-title":"Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients","volume":"7","author":"Markou","year":"2003","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.idc.2025.11.001_bib72","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib73","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.idc.2025.11.001_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1469-0691.2004.01043.x","article-title":"Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the Renaissance of an old antibiotic","volume":"11","author":"Michalopoulos","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.11.001_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","article-title":"Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections","volume":"37","author":"Montero","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.idc.2025.11.001_bib76","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2025.11.001_bib77","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/antibiotics12081317","article-title":"Comparison between colistin and polymyxin B in the treatment of bloodstream infections caused by carbapenem-resistant pseudomonas aeruginosaand acinetobacter baumannii-calcoaceticus complex","volume":"12","author":"Garcia","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idc.2025.11.001_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02595-16","article-title":"Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections","volume":"61","author":"Luque","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-11-317","article-title":"A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa","volume":"11","author":"Tamma","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib80","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","article-title":"Efficacy of high-dose nebulized colistin in ventilator associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"117","author":"Lu","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.idc.2025.11.001_bib81","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/432583","article-title":"Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"41","author":"Kwa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib82","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gramnegative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib83","first-page":"425","article-title":"Aminoglycosides against pseudomonas aeruginosa: should we keep using them?","volume":"13","author":"Zavascki","year":"2015","journal-title":"Expert Review Anti Infect Ther"},{"key":"10.1016\/j.idc.2025.11.001_bib84","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40121-021-00570-z","article-title":"Aminoglycoside or polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant pseudomonas aeruginosa: a propensity score-adjusted and matched cohort study","volume":"11","author":"L\u00f3pez Montesinos","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idc.2025.11.001_bib86","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4103\/0366-6999.205846","article-title":"Aerosolized amikacin as adjunctive therapy of ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria: a single-center randomized controlled trial","volume":"130","author":"Liu","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.idc.2025.11.001_bib87","doi-asserted-by":"crossref","first-page":"e01121","DOI":"10.1128\/JCM.01121-20","article-title":"Performance of four fosfomycin susceptibility testing methods against an international collection of clinical Pseudomonas aeruginosa isolates","volume":"58","author":"Smith","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2025.11.001_bib88","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jac\/dkaa127","article-title":"Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model","volume":"75","author":"Abbott","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib89","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib90","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model","volume":"73","author":"Bilal","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib91","doi-asserted-by":"crossref","first-page":"e00126","DOI":"10.1128\/AAC.00126-19","article-title":"Pharmacodynamic attainment of the synergism of meropenem and fosfomycin combination against Pseudomonas aeruginosa producing metallo-\u03b2-lactamase","volume":"63","author":"Albiero","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib92","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib93","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib94","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/jac\/dkae296","article-title":"Impact of adequate empirical combination therapy on mortality in septic shock due to P. aeruginosa bloodstream infections","volume":"79","author":"Vena","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.001_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00585-21","article-title":"Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates","volume":"9","author":"Montero","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.idc.2025.11.001_bib96","doi-asserted-by":"crossref","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of CZA in combination with meropenem, Amikacin, Aztreonam, Colistin, or fosfomycin against MDR K. pneumoniae and P. aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02542-19","article-title":"Efficacy of ceftolozane-tazobactam in combination with Colistin against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones, in an in vitro pharmacodynamic model","volume":"64","author":"Montero","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib98","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2025.11.001_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"Diaz-Canestro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib101","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.idc.2025.11.001_bib102","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijantimicag.2018.09.008","article-title":"Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia","volume":"52","author":"Khawcharoenporn","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Fosfomycin combination regimens for difficult-to-treat infections due to MDR gram-negatives: a real-life experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib104","doi-asserted-by":"crossref","first-page":"e00026","DOI":"10.1128\/AAC.00026-18","article-title":"Evaluation of ceftolozane-tazobactam in combination with Meropenem against Pseudomonas aeruginosa sequence type 175 in a hollow-fiber infection model","volume":"62","author":"Montero","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf112","article-title":"Rapid valve sterilization with meropenem plus ceftolozane\/tazobactam combination therapy for Pseudomonas aeruginosa prosthetic valve endocarditis","volume":"7","author":"Alaguvel","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.001_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01118-23","article-title":"Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through \u03b2-lactam-enhancer-mechanism-based cefepime\/zidebactam","volume":"14","author":"Hujer","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.idc.2025.11.001_bib107","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent \u201c\u03b2-Lactam Enhancer\u201d activity against Pseudomonas aeruginosa, including multidrug-resistant Metallo-\u03b2-Lactamase-Producing high-risk clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib108","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","article-title":"Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa","volume":"75","author":"Moya","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib109","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00500-23","article-title":"Successful use of cefepime-zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant new Delhi Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa infection in an adult patient with acute T-Cell leukemia","volume":"67","author":"Tirlangi","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"25","key":"10.1016\/j.idc.2025.11.001_bib111","first-page":"00164","article-title":"Successful use of cefepime\/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa - a case series","volume":"S2213-7165","author":"Shah","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.001_bib112","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-024-04791-1","article-title":"Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime\/zidebactam (WCK 5222)","author":"Soman","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib113","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/trstmh\/trae049","article-title":"Difficult to treat Pseudomonas: successful salvage therapy with cefepime-zidebactam","volume":"118","author":"Sebastian","year":"2024","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.idc.2025.11.001_bib114","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10096-025-05106-8","article-title":"Investigational antibiotic cefepime\/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report","volume":"44","author":"Polati","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf129","article-title":"Cefepime-zidebactam therapy for extensively drug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae infection as a bridge to liver transplantation","volume":"7","author":"Tsai","year":"2025","journal-title":"JAC Antimicrob Resist"},{"issue":"10","key":"10.1016\/j.idc.2025.11.001_bib116","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/jac\/dkab213","article-title":"In vitro evolution of cefepime\/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy","volume":"76","author":"Barcel\u00f3","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib117","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic antibacterial activity of xeruborbactam in vitro: assessing spectrum and mode of action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib118","article-title":"In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria","volume":"68","author":"Takemoto","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib119","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00739-21","article-title":"Single- and multiple-ascending-dose study of the safety, tolerability, and pharmacokinetics of the polymyxin derivative SPR206","volume":"65","author":"Bruss","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00505-23","article-title":"Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment","volume":"67","author":"Bruss","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib121","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00426-23","article-title":"Pharmacokinetics of SPR206 in plasma, pulmonary epithelial lining fluid, and alveolar macrophages following intravenous administration to healthy adult subjects","volume":"67","author":"Rodvold","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib122","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41467-022-29234-3","article-title":"A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens","volume":"13","author":"Roberts","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.idc.2025.11.001_bib123","series-title":"In vitro activity of BWC0977 (a novel bacterial topoisomerase inhibitor) and comparators against recent clinical and molecularly characterized Enterobacteriaceae and non-fermenter isolates from the United States and Europe","author":"Huband","year":"2019"},{"key":"10.1016\/j.idc.2025.11.001_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jgar.2023.02.005","article-title":"In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates","volume":"33","author":"Cam\u00e9l\u00e9na","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.11.001_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106659","article-title":"Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia","volume":"60","author":"Gysin","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.001_bib126","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib127","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.idc.2025.11.001_bib128","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.idc.2025.11.001_bib129","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s10096-014-2156-1","article-title":"Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia","volume":"33","author":"Que","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.001_bib130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12866-021-02427-4","article-title":"Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection","volume":"22","author":"Nasrin","year":"2022","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.idc.2025.11.001_bib131","series-title":"COT-143, a novel monoclonal antibody against the PcrV protein: Binding affinity against PcrV and in vitro cytotoxicity inhibitory activity against Pseudomonas aeruginosa","author":"Maki","year":"2018"},{"key":"10.1016\/j.idc.2025.11.001_bib132","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00203-022-03068-5","article-title":"Regulation of T3SS synthesis, assembly and secretion in Pseudomonas aeruginosa","volume":"204","author":"Selim","year":"2022","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.idc.2025.11.001_bib133","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/antibiotics11010104","article-title":"Crumbling the castle: targeting DNABII proteins for collapsing bacterial biofilms as a therapeutic approach to treat disease and combat antimicrobial resistance","volume":"11","author":"Rogers","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idc.2025.11.001_bib134","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01942-24","article-title":"Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel \u03b2-Lactams in Pseudomonas aeruginosa","volume":"69","author":"Sastre-Femenia","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.001_bib135","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/phar.2449","article-title":"Approach to the treatment of patients with serious multidrug-resistant Pseudomonas aeruginosa infections","volume":"40","author":"O\u2019Donnell","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2025.11.001_bib136","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkae263","article-title":"Impact of chromosomally encoded resistance mechanisms and transferable \u03b2-Lactamases on the activity of cefiderocol and innovative \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations against Pseudomonas aeruginosa","volume":"79","author":"Gonz\u00e1lez-Pinto","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:41:53Z","timestamp":1773780113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0891552025000959"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.001","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Management Strategies of Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}